Reporting on sex-based analysis in clinical trials of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker efficacy

Canadian Journal of Cardiology

Volumn 24, Issue 6, 2008, Pages 491-496

  Rabi, Doreen M ^a,d   Khan, N ^b   Vallee, M ^c   Hladunewich, M A ^d   Tobe, S W ^d   Pilote, L ^d  

^a UNIVERSITY OF CALGARY   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d NONE

Author keywords

ACE inhibitors; Angiotensin receptor blockers; Efficacy; Hypertension; Sex

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CANDESARTAN HEXETIL; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPROSARTAN; FOSINOPRIL; IMIDAPRIL; INDAPAMIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; METOPROLOL; NIFEDIPINE; NISOLDIPINE; NITRENDIPINE; PERINDOPRIL; PLACEBO; RAMIPRIL; TELMISARTAN; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VALSARTAN;

ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; EFFECT SIZE; EVIDENCE BASED MEDICINE; HUMAN; HYPERTENSION; MEDICAL LITERATURE; OUTCOME ASSESSMENT; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SECONDARY PREVENTION; SEX DIFFERENCE; STROKE; SYSTEMATIC REVIEW; MORBIDITY; PATIENT COMPLIANCE; REVIEW; SEX RATIO; TREATMENT OUTCOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; HUMANS; HYPERTENSION; MORBIDITY; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEX DISTRIBUTION; SEX FACTORS; TREATMENT OUTCOME;

EID: 46249087605     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(08)70624-X     Document Type: Article

References (42)

1. Joffres MR, Hamet P, MacLean DR, L'italien GJ, Fodor G. Distribution of blood pressure and hypertension in Canada and the United States. Am J Hypertens 2001;14:1099-105.
2. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003;289:2363-9.
3. Yusuf S, Hawken S, Ounpuu S, et al; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004;364:937-52.
4. Joffres MR, Ghadirian P, Fodor JG, Petrasovits A, Chockalingam A, Hamet P. Awareness, treatment, and control of hypertension in Canada. Am J Hypertens 1997;10:1097-102.
5. Gradman AH, Kad R. Renin inhibition in hypertension. J Am Coll Cardiol 2008;51:519-28.
6. Hammoud RA, Vaccari CS, Nagamia SH, Khan BV. Regulation of the renin-angiotensin system in coronary atherosclerosis: A review of the literature. Vasc Health Risk Manag 2007;3:937-45.
7. Reckelhoff JF. Gender differences in the regulation of blood pressure. Hypertension 2001;37:1199-208.
8. Izumi Y, Matsumoto K, Ozawa Y, et al. Effect of age at menopause on blood pressure in postmenopausal women. Am J Hypertens 2007;20:1045-50.
9. McGuire BB, Watson RW, Pérez-Barriocanal F, Fitzpatrick JM, Docherty NG. Gender differences in the renin-angiotensin and nitric oxide systems: Relevance in the normal and diseased kidney. Kidney Blood Press Res 2007;30:67-80.
10. Pilote L, Dasgupta K, Guru V, et al. A comprehensive view of sex-specific issues related to cardiovascular disease. CMAJ 2007;176:S1-44. (Erratum in 2007;176:1310).
11. Franklin SS. Definition and epidemiology of hypertensive cardiovascular disease in women: The size of the problem. J Hypertens Suppl 2002;20:S3-S5.
12. Geller SE, Adams MG, Carnes M. Adherence to federal guidelines for reporting of sex and race/ethnicity in clinical trials. J Womens Health (Larchmt) 2006;15:1123-31.
13. Pinn VW. The role of the NIH's Office of Research on Women's Health. Acad Med 1994;69:698-702.
14. Rochon PA, Clark JP, Binns MA, Patel V, Gurwitz JH. Reporting of gender-related information in clinical trials of drug therapy for myocardial infarction. CMAJ 1998;159:321-7. (Erratum in 1998;159:650).
15. Campbell NR, Tu K, Brant R, Duong-Hua M, McAlister FA; Canadian Hypertension Education Program Outcomes Research Task Force. The impact of the Canadian Hypertension Education Program on antihypertensive prescribing trends. Hypertension 2006;47:22-8.
16. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: A network meta-analysis. JAMA 2003;289:2534-44.
17. Rodrigues EJ, Eisenberg MJ, Pilote L. Effects of early and late administration of angiotensin-converting enzyme inhibitors on mortality after myocardial infarction. Am J Med 2003;115:473-9.
18. The Captopril Prevention Project: A prospective intervention trial of angiotensin converting enzyme inhibition in the treatment of hypertension. The CAPPP Group. J Hypertens 1990;8:985-90.
19. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998;317:713-20.
20. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41. (Errata in 2001;358:1556, 2002;359:2120).
21. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97. (Errata in 2003;289:178, 2004;291:2196).
22. Barnett AH, Bain SC, Bouter P, et al; Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004;351:1952-61. (Erratum in 2005;352:1731).
23. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8.
24. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751-6.
25. Schrier RW, Estacio RO. Additional follow-up from the ABCD trial in patients with type 2 diabetes and hypertension. N Engl J Med 2000;343:1969.
26. Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998;21:597-603.
27. Wing LM, Reid CM, Ryan P, et al; Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting - enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003;348:583-92.
28. Wright JT Jr, Bakris G, Greene T, et al; African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 2002;288:2421-31. (Erratum in 2006;295:2726).
29. Yui Y, Sumiyoshi T, Kodama K, et al; Japan Multicenter Investigation for Cardiovascular Diseases-B Study Group. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: The Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens Res 2004;27:181-91.
30. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53. (Errata in 2000;342:1376, 2000;342:748).
31. Kizer JR, Dahlöf B, Kjeldsen SE, et al. Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: The Losartan Intervention For Endpoint reduction in hypertension study. Hypertension 2005;45:46-52.
32. Lewis EJ, Hunsicker LG, Clarke WR, et al; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
33. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Amer P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.
34. Schrader J, Lüders S, Kulschewski A, et al; Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS Study: Evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 2003;34:1699-703.
35. Schrader J, Lüders S, Kulschewski A, et al; MOSES Study Group. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: Principal results of a prospective randomized controlled study (MOSES). Stroke 2005;36:1218-26.
36. Suzuki H, Kanno Y; Efficacy of Candesartan on Outcome in Saitama Trial (E-COST) Group. Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients. Hypertens Res 2005;28:307-14. (Erratum in 2005;28:553).
37. Trenkwalder P, Elmfeldt D, Hofman A, et al; The Study on COgnition and Prognosis in the Elderly (SCOPE). The Study on COgnition and Prognosis in the Elderly (SCOPE) - major CV events and stroke in subgroups of patients. Blood Press 2005;14:31-7.
38. Zanchetti A, Julius S, Kjeldsen S, et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial. J Hypertens 2006;24:2163-8.
39. Okin PM, Devereux RB, Jern S, et al; Losartan Intervention for Endpoint reduction in hypertension Study Investigations. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. Circulation 2003;108:684-90.
40. Hudson M, Rahme E, Behlouli H, Sheppard R, Pilote L. Sex differences in the effectiveness of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in patients with congestive heart failure - a population study. Eur J Heart Fail 2007;9:602-9.
41. Keyhan G, Chen SF, Pilote L. Angiotensin-converting enzyme inhibitors and survival in women and men with heart failure. Eur J Heart Fail 2007;9:594-601.
42. Miller JA, Cherney DZ, Duncan JA, et al. Gender differences in the renal response to renin-angiotensin system blockade. J Am Soc Nephrol 2006;17:2554-60.